Source comparison
Thymosin Alpha-1 Safe Side Effects: Clinical Trial Data Comparison
| Trial Population | Sample Size | Tα1 Dose & Duration | Injection-Site Reactions | Systemic AEs | Serious AEs | Professional Assessment ||—|—|—|—|—|—|| Chronic Hepatitis B (Wu et al., 2013) | 234 patients | 1.6mg SC twice weekly, 24 weeks | 11.2% | 4.1% (fati
This comparison does not assign a generated winner or score.
- | Trial Population | Sample Size | Tα1 Dose & Duration | Injection-Site Reactions | Systemic AEs | Serious AEs | Professional Assessment ||—|—|—|—|—|—|| Chronic Hepatitis B (Wu et al., 2013) | 234 patients | 1.6mg SC twice weekly, 24 weeks | 11.2% | 4.1% (fatigue, myalgia) | 0.9% (unrelated to Tα1) | Well-tolerated in long-term viral suppression context; no hepatotoxicity signals || Metastatic Melanoma (Garaci et al., 2003) | 186 patients | 3.2mg SC twice weekly, 52 weeks | 14.5% | 6.3% (flu-like symptoms) | 1.1% (disease progression, not treatment-related) | Safe adjunct to chemotherapy; no additive toxicity with dacarbazine || Sepsis (Wu et al., 2013) | 361 ICU patients | 1.6mg SC daily, 7 days | 8.7% | 2.8% (transient fever) | 1.4% (multiorgan failure, baseline critical illness) | No increase in infection risk or immune dysregulation in critically ill || Elderly Vaccination Response (Scolaro et al., 2013) | 143 subjects (age 65+) | 1.6mg SC twice weekly, 4 weeks | 9.8% | 3.5% (fatig